Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Cognitive behavioral therapy (CBT) is not a molecule, receptor, or biological target; rather, it is a structured, evidence-based form of **psychotherapy** designed to modify dysfunctional thoughts, emotions, and behaviors to improve mental health and well-being[1][5][9][10]. Because of this, it should not be classified as a druggable target, receptor, enzyme, or molecular entity. Cognitive behavioral therapy (CBT) is a form of **psychological treatment** that aims to reduce symptoms of mental health conditions such as depression, anxiety, post-traumatic stress disorder (PTSD), eating disorders, substance use disorders, and many others. It is based on the principle that maladaptive thinking patterns and behaviors contribute to emotional distress, and that modifying these patterns can lead to improvements in functioning and quality of life. CBT is highly structured, time-limited, problem-oriented, and often involves homework, goal setting, and skill-building exercises. It is typically conducted over several weekly sessions with a licensed therapist, either alone or in combination with other treatments such as medication[1][3][6][7][9][10].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Cognitive behavioral therapy (CBT).